Risperidone in pervasive developmental disorders

Expert Review of Neurotherapeutics

Volumn 5, Issue 6, 2005, Pages 713-719

  Erickson, Craig A ^b   Stigler, Kimberly A ^a   Posey, David J ^b   McDougle, Christopher J ^b  

^a Riley Child Psychiatry Clinic   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Aggression; Autism; Pervasive developmental disorder; Risperidone; Self injurious behavior

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; PALIPERIDONE; PLACEBO; PROLACTIN; RISPERIDONE; VALPROIC ACID;

AUTISM; BIPOLAR I DISORDER; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; INCREASED APPETITE; LIVER TOXICITY; METABOLIC SYNDROME X; MOTOR DYSFUNCTION; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TARDIVE DYSKINESIA; TIC; TREATMENT OUTCOME; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DIABETES MELLITUS; EXPERT TESTIMONY; HUMANS; META-ANALYSIS; METABOLIC DISEASES; MOVEMENT DISORDERS; PROLACTIN; RISPERIDONE; WEIGHT GAIN;

EID: 27944502140     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.6.713     Document Type: Review

References (30)

1. Campbell M, Anderson LT, Meier M et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry 17, 640-655 (1978).
2. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry 36, 835-843 (1997).
3. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT. Behavioral effects of haloperidol in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 19, 665-677 (1980).
4. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J. Autism. Dev. Disord. 19, 227-239 (1989).
5. Volkmar F, Cook EH, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J. Am. Acad. Child Adolesc. Psychiatry 38(Suppl. 12), S32-S54 (1999).
6. Aman MG, Lam KS, Van Dourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J. Child Adolesc. Psychopharmacol. 15(1), 116-126 (2005).
7. Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Psychopharmacology. In: Autism and Pervasive Developmental Disorders (Second Edition). Volkmar FR (Ed.). Cambridge University Press, Cambridge, UK (2005) (In Press).
8. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull. 33(1), 155-159 (1997).
9. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J. Autism Dev. Disord. 27(3), 313-323 (1997).
10. Perry R, Pataki C, Munox-Silva DM, Armenteros J, Silva RR. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J. Child Adolesc. Psychopharmacol. 7(3), 167-179 (1997).
11. McDougle CJ, Holmes JP, Bronson MR et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J. Am. Acad. Child Adolesc. Psychiatry 36(5), 685-693 (1997).
12. Zuddas A, DiMartino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J. Child Adolesc. Psychopharmacol. 10(2), 79-90 (2000).
13. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J. Am. Acad. Child Adolesc. Psychiatry 41(2), 140-147 (2002).
14. Nicolson R, Awad G, Sloman L. An open label trial of risperidone in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 37(4), 372-376 (1998).
15. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorder. J. Am. Acad. Child Adolesc. Psychiatry 40(10), 1206-1214 (2001).
16. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J. Clin. Psychiatry 64(9), 1039-1047 (2003).
17. Gagliano A, Germano E, Pustorino G et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J. Child Adolesc. Psychopharmacol. 14(1), 39-47 (2004).
18. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 55, 633-641 (1998). Pivotal double-blind trial in adults with autism/pervasive developmental disorder not otherwise specified.
19. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N. Engl J. Med. 347(5), 314-321 (2002). Pivotal double-blind trial in children with autism.
20. Arnold LE, Vitiello B, McDougle CJ et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J. Am. Acad. Child Adolesc. Psychiatry 42(12), 1443-1450 (2003).
21. Research Units of Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry 162(7), 1361-1369 (2005).
22. Shea S, Turgay A, Carroll A et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5), e634-e641 (2005).
23. Martin A, Scahill L, Anderson GM et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am. J. Psychiatry 161(6), 1125-1127 (2004).
24. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J. Child Adolesc. Psychopharmacol. 11(3), 229-238 (2001).
25. Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr. Drugs 6(1), 33-44 (2004).
26. Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc. Psychopharmacol. 11(4), 389-394 (2001).
27. Kwon H. Tardive dyskinesia in an autistic patient treated with risperidone. Am. J. Psychiatry 161(4), 757-758 (2004).
28. Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J. Child Adolesc. Psychopharmacol. 9(4), 273-276 (1999).
29. McDougle CJ, Scahill L, Aman MG et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 162(6), 1142-1148 (2005).
30. Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised Edition). DHHS Publication No. ADM 91-338. US Department of Health, Education, and Welfare, DC, USA, (1976).